Conflicts of interest: None.
The role of the human papillomavirus (HPV) vaccine in developing countries
Article first published online: 15 MAR 2010
© 2010 The International Society of Dermatology
International Journal of Dermatology
Volume 49, Issue 4, pages 377–379, April 2010
How to Cite
Kling, M. and Zeichner, J. A. (2010), The role of the human papillomavirus (HPV) vaccine in developing countries. International Journal of Dermatology, 49: 377–379. doi: 10.1111/j.1365-4632.2010.04316.x
- Issue published online: 15 MAR 2010
- Article first published online: 15 MAR 2010
Cervical cancer is a preventable health problem, yet is the second most common cancer of women worldwide. More than 80% of cases occur in developing countries, and this is expected to increase to 90% by the year 2020. The five-year survival rate of patients in developing countries is less than 50%, compared to 66% in developed nations. A worldwide HPV vaccine program would significantly reduce the spread of HPV 16 and 18 and lower the incidence of cervical cancer. Mathematical models have determined that vaccinating 66% of the population will decrease the incidence of cervical cancer by 80% over the next 40–60 years. For every five-year delay in a cervical cancer prevention/detection program, there will be an additional 1.5–2.0 million deaths. The introduction of a vaccination program will be a challenge due to high costs, unknown durability of the vaccine, and the potential for new oncogenic strains to emerge. A global effort will be required to eliminate cervical cancer from developing counties.